ArticleFrontiers in endocrinology2025
Free triiodothyronine and triglyceride-glucose index interaction on metabolic dysfunction-associated steatotic liver disease risk in euthyroid individuals.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The link between thyroid function and insulin resistance and metabolic dysfunction-associated fatty liver disease (MASLD) is becoming increasingly recognized. The primary goal of this study was to investigate the relationship between free triiodothyronine (FT3) levels, the triglyceride-glucose index (TyG) index, and the likelihood of MASLD in euthyroid individuals. Methods: A cross-sectional analysis of 18,298 euthyroid individuals was conducted, comparing 6,144 with MASLD to 12,154 controls. The study evaluated indicators related to clinical, metabolic, and thyroid function. The combined effect of the FT3 and TyG index on the likelihood of MASLD was assessed using logistic regression. Results: The MASLD group presented with higher male prevalence, older age, and increased rates of hypertension and diabetes. Significant correlations were observed between FT3, TyG, and metabolic parameters. After controlling for potential confounders, FT3 remained significantly associated with increased MASLD risk (adjusted OR = 1.35, 95% CI: 1.23-1.49; Conclusion: Elevated FT3 and TyG index are independently associated with an increased risk of MASLD, and they exhibit a significant synergistic additive interaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.